LabCorp to offer Exact's colorectal cancer test
This article was originally published in Clinica
Laboratory Corporation of America is to pay up to $75m for a five-year, exclusive licence to Exact Sciences' PreGen-Plus, a proprietary DNA-based noninvasive technology for the early detection of colorectal cancer in the average-risk population. After five years, LabCorp will have a non-exclusive licence for the life of the patents. The launch of the product is expected in first half of 2003.
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.